MarketIQ Analyst Report for American Rebel Holdings Inc

718 THOMPSON LANE, STE 108-199, NASHVILLE, TN, US
AREB

Last Updated: 14 Oct 2024

Executive Summary

American Rebel Holdings Inc. (AREB) is a small-cap stock trading on the NASDAQ exchange. The company manufactures and sells safes and personal security products. AREB reported a net loss of $12.29 million for the fiscal year ended December 2023, on revenue of $15.45 million. The company's financial performance has been impacted by rising input costs and supply chain disruptions.

Company Overview

American Rebel Holdings Inc. was founded in 2010 and is headquartered in Nashville, Kansas. The company's products are sold through a network of distributors and retailers. AREB's main competitors include SentrySafe, GunVault, and Stack-On.

Fundamental Analysis

AREB's financial performance has been weak in recent years. The company has reported net losses in each of the past three fiscal years. AREB's gross margin has also declined in recent quarters, due to rising input costs. The company's profitability is likely to remain under pressure in the near term.

Technical Analysis

AREB's stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The technical indicators suggest that the stock is likely to continue to decline in the near term.

Short Term Outlook

AREB's short-term outlook is negative. The company's financial performance is weak and the stock price is in a downtrend. Investors should avoid buying AREB stock until the company shows signs of improvement.

Long Term Outlook

AREB's long-term outlook is uncertain. The company's financial performance is likely to improve if the economy recovers and input costs decline. However, AREB faces competition from larger and more established companies. Investors should only consider buying AREB stock if they are willing to take on a high level of risk.

Analyst Recommendations

The majority of analysts have a "hold" rating on AREB stock. The consensus price target is $2.00, which is below the current market price.